{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:11:04Z","timestamp":1791389464226,"version":"4.3.3"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alopecia areata (AA) is a common autoimmune hair loss disorder with a highly variable course and substantial psychosocial impact. Evidence from long-term prospective cohorts remains limited. To characterize the natural history, treatment outcomes, relapse patterns, quality-of-life changes, and safety profile of AA over 52 weeks in a real-world clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center prospective cohort, 400 patients with AA and 80 healthy controls were followed for 52 weeks, with assessments at weeks 4, 12, 24, 36, and 52. Disease severity was quantified using the Severity of Alopecia Tool (SALT). Primary outcomes included SALT50 and SALT90 achievement at week 24; secondary outcomes were relapse at week 52, patient-reported outcomes [Dermatology Life Quality Index (DLQI), Skindex-16, itch\/pain numeric rating scale (NRS)], and safety. An imaging subcohort (\n                      <jats:italic>n<\/jats:italic>\n                      = 120) underwent dermoscopy and high-frequency ultrasound. Statistical analyses comprised mixed-effects models, logistic and Cox regression, ROC analyses, and correlation testing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      By week 52, 31.8% of patients relapsed, with a median relapse time of 28 weeks. SALT improved over time, with mean scores declining from 38.6 \u00b1 21.7 at baseline to 22.4 \u00b1 17.1 at week 52 (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). At week 24, 62.5% achieved SALT50 and 28.3% achieved SALT90, with active disease, shorter duration, and younger age predicting better outcomes. ROC analysis showed improved discrimination for the enhanced model including activity and duration (AUC 0.81 vs. 0.69,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006). By week 52, 31.8% relapsed (median time 28 weeks), with relapse risk highest in those with prior episodes (HR 1.61, 95% CI 1.17\u20132.21). Quality-of-life indices improved significantly (DLQI \u22127.1, Skindex-16 \u221215.4 from baseline to week 52, both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001), and itch\/pain reduction correlated with SALT improvement (\n                      <jats:italic>r<\/jats:italic>\n                      = 0.41 and 0.23, respectively). Dermoscopic and ultrasound parameters correlated with baseline severity and improved prediction of therapeutic response (AUC up to 0.84).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This prospective cohort provides longitudinal evidence that baseline severity, disease activity, and relapse history are major determinants of response and recurrence in AA. Standardized severity scores, patient-reported outcomes, and imaging biomarkers may improve risk stratification, personalized care, and real-world evaluation of current therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1695618","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:17Z","timestamp":1763097017000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study"],"prefix":"10.3389","volume":"12","author":[{"given":"Yan","family":"Wenjie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Mengjiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yumei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1111\/1346-8138.14863","article-title":"Increasing prevalence of alopecia areata in South Korea.","volume":"46","author":"Soh","year":"2019","journal-title":"J Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/jdv.18733","article-title":"Prevalence and implications of type D personality in patients with alopecia areata: A marker of quality-of-life impairment and mood status disturbances, a comparative study.","volume":"37","author":"Sanchez-Diaz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population.","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamadermatol.2022.0351","article-title":"Evaluation of the prevalence and incidence of Pediatric alopecia areata using electronic health record data.","volume":"158","author":"McKenzie","year":"2022","journal-title":"JAMA Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/bjd.18145","article-title":"Incidence and prevalence of alopecia areata according to subtype: a nationwide, population-based study in South Korea (2006-2015).","volume":"181","author":"Lee","year":"2019","journal-title":"Br J Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamadermatol.2022.6085","article-title":"Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis.","volume":"159","author":"Lauron","year":"2023","journal-title":"JAMA Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12026-019-09104-9","article-title":"The prevalence of systemic sclerosis is increased among patients with alopecia areata: a population-based study.","volume":"67","author":"Kridin","year":"2019","journal-title":"Immunol Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1111\/jdv.16864","article-title":"Prevalence of cardiac and metabolic diseases among patients with alopecia areata.","volume":"35","author":"Conic","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.2147\/JIR.S331579","article-title":"Prevalence and Risk Factors Associated with the Occurrence of Autoimmune Diseases in Patients with Alopecia Areata.","volume":"14","author":"Chanprapaph","year":"2021","journal-title":"J Inflamm Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/1346-8138.16615","article-title":"Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: a descriptive study using Japan medical data center claims database.","volume":"50","author":"Campos-Alberto","year":"2023","journal-title":"J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","article-title":"A large cross-sectional survey study of the prevalence of alopecia areata in the United States.","volume":"13","author":"Benigno","year":"2020","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/1346-8138.16606","article-title":"Prevalence of alopecia areata in Japan: estimates from a nationally representative sample.","volume":"50","author":"Aranishi","year":"2023","journal-title":"J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7194270","DOI":"10.1155\/2020\/7194270","article-title":"Prevalence and clinical characteristics of alopecia areata at a tertiary care center in Saudi Arabia.","volume":"2020","author":"Alshahrani","year":"2020","journal-title":"Dermatol Res Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e10347","DOI":"10.7759\/cureus.10347","article-title":"Prevalence of alopecia areata in Saudi Arabia: cross-sectional descriptive study.","volume":"12","author":"Al-Ajlan","year":"2020","journal-title":"Cureus."},{"key":"B15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12911-025-02853-8","article-title":"Identifying effective immune biomarkers in alopecia areata diagnosis based on machine learning methods.","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Med Inform Decis Mak."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e13579","DOI":"10.1111\/srt.13579","article-title":"Causal role of immune cells in alopecia areata: a two-sample mendelian randomization study.","volume":"30","author":"Xu","year":"2024","journal-title":"Skin Res Technol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"bad009","DOI":"10.1093\/pcmedi\/pbad009","article-title":"Construction of regulatory network for alopecia areata progression and identification of immune monitoring genes based on multiple machine-learning algorithms.","volume":"6","author":"Xiong","year":"2023","journal-title":"Precis Clin Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"110880","DOI":"10.1016\/j.intimp.2023.110880","article-title":"Identifying immuno-related diagnostic genes and immune infiltration signatures for periodontitis and alopecia areata.","volume":"124","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1684\/ejd.2022.4315","article-title":"Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors.","volume":"32","author":"Suzuki","year":"2022","journal-title":"Eur J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1093\/ibd\/izab005","article-title":"Tofacitinib for the treatment of three immune-mediated conditions in one patient: ulcerative colitis, pyoderma gangrenosum, and alopecia areata.","volume":"27","author":"Sedano","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1016\/j.jid.2025.04.024","article-title":"Lessons from TNF-alpha inhibitor-induced alopecia areata: does TNF-alpha operate as a hair follicle immune privilege guardian under inflammatory conditions?","volume":"145","author":"Perez","year":"2025","journal-title":"J Invest Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/jamadermatol.2024.2404","article-title":"Immune-mediated and psychiatric comorbidities among patients newly diagnosed with alopecia areata.","volume":"160","author":"Mostaghimi","year":"2024","journal-title":"JAMA Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.humimm.2010.04.003","article-title":"Computer-aided human leukocyte antigen association studies: a case study for psoriasis and severe alopecia areata.","volume":"71","author":"Catanzaro","year":"2010","journal-title":"Hum Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/sj.jid.5700973","article-title":"Human leukocyte antigen class II alleles are associated with risk of alopecia areata.","volume":"128","author":"Barahmani","year":"2008","journal-title":"J Invest Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00403-022-02444-x","article-title":"Immune-mediated diseases and subsequent risk of alopecia areata in a prospective study of US women.","volume":"315","author":"Moseley","year":"2023","journal-title":"Arch Dermatol Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/skinhd\/vzae019","article-title":"Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report.","volume":"5","author":"Moon","year":"2025","journal-title":"Skin Health Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jocd.15465","article-title":"Herpes zoster and alopecia areata following mRNA BNT162b2 COVID-19 vaccine: controversial immune effects.","volume":"22","author":"Martora","year":"2023","journal-title":"J Cosmet Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/ijd.17895","article-title":"Immune-mediated disorders in patients with alopecia areata: systematic review and meta-analysis.","volume":"64","author":"Krajewski","year":"2025","journal-title":"Int J Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e19430","DOI":"10.7717\/peerj.19430","article-title":"Unveiling the immune and vitamin profiles of blood: the potential biomarkers for alopecia areata.","volume":"13","author":"Ke","year":"2025","journal-title":"PeerJ."},{"key":"B30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jaad.2025.03.085","article-title":"Baricitinib and oral minoxidil for the treatment of alopecia areata in pediatric patients.","volume":"93","author":"Valido","year":"2025","journal-title":"J Am Acad Dermatol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.05.034","article-title":"Predominance of CD27(-)PD-1(-) effector memory T cells re-expressing CD45RA characterizes treatment-resistant severe alopecia areata.","author":"Takahashi","year":"2025","journal-title":"J Invest Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s13555-025-01425-y","article-title":"Real-world evidence for baricitinib in the treatment of atopic dermatitis and alopecia areata: systematic literature review 2020-2023.","volume":"15","author":"Seneschal","year":"2025","journal-title":"Dermatol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1684\/ejd.2025.4862","article-title":"Complete therapeutic response to upadacitinib as a continued treatment for alopecia areata universalis.","volume":"35","author":"Machado","year":"2025","journal-title":"Eur J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40257-025-00932-0","article-title":"Safety of baricitinib in adults with severe alopecia areata from two phase III trials over a median of 2.3 years and up to 4 years of treatment.","volume":"26","author":"King","year":"2025","journal-title":"Am J Clin Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"25869","DOI":"10.1038\/s41598-025-07224-x","article-title":"Global burden of alopecia areata from 1990 to 2019 and emerging treatment trends analyzed through GBD 2019 and bibliometric data.","volume":"15","author":"Ding","year":"2025","journal-title":"Sci Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/diagnostics15111369","article-title":"Serum-based assessment of alopecia areata response to treatment using ATR-FTIR spectroscopy.","volume":"15","author":"Delrue","year":"2025","journal-title":"Diagnostics."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_439_2022","article-title":"Comparison of self-estimated and clinician-measured SALT score in patients with alopecia areata: Patients with alopecia areata perceive themselves as more severe than dermatologists.","author":"Yeong Lee","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20698","article-title":"SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata.","author":"Reguiai","year":"2025","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/jocd.12664","article-title":"Correlation between serum IL-17A level and SALT score in patients with alopecia areata before and after NB-UVB therapy.","volume":"17","author":"Morsy","year":"2018","journal-title":"J Cosmet Dermatol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17870","article-title":"Innovative approaches to the assessment of alopecia areata: incorporating the SALT index through transparent devices.","author":"Moron-Ocana","year":"2025","journal-title":"Int J Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00403-025-04026-z","article-title":"Evaluation of SALT score severity in correlation with trichoscopic findings in alopecia areata: a study of 303 patients.","volume":"317","author":"Kaya","year":"2025","journal-title":"Arch Dermatol Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2422909","DOI":"10.1080\/09546634.2024.2422909","article-title":"Complete responses and SALT zero scores in alopecia areata: not the same.","volume":"35","author":"Donovan","year":"2024","journal-title":"J Dermatolog Treat."},{"key":"B43","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.jisp.2017.10.010","article-title":"Quantifying alopecia areata via texture analysis to automate the SALT score computation.","volume":"19","author":"Bernardis","year":"2018","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40257-024-00884-x","article-title":"Predictors and management of inadequate response to JAK inhibitors in alopecia areata.","volume":"25","author":"Zhang","year":"2024","journal-title":"Am J Clin Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/milmed\/usae292","article-title":"A review of JAK inhibitors for treatment of alopecia areata in the military health care system.","volume":"190","author":"Song","year":"2025","journal-title":"Mil Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00403-024-03325-1","article-title":"Analysis of patient experiences regarding JAK inhibitors for atopic dermatitis, psoriasis, alopecia areata, and vitiligo.","volume":"316","author":"Sharma","year":"2024","journal-title":"Arch Dermatol Res."},{"key":"B47","first-page":"313","article-title":"Reddit analysis reveals common questions of patients with alopecia areata about JAK inhibitors for hair loss.","volume":"22","author":"Konisky","year":"2024","journal-title":"Skinmed."},{"key":"B48","doi-asserted-by":"publisher","first-page":"4s83","DOI":"10.1007\/s00403-024-03177-9","article-title":"Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and contact immunotherapy in the treatment of severe alopecia areata: a systematic review and network meta-analysis.","volume":"316","author":"Guan","year":"2024","journal-title":"Arch Dermatol Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00403-025-04035-y","article-title":"Switching JAK inhibitors: evaluating baricitinib\u2019s effectiveness in alopecia areata after tofacitinib failure.","volume":"317","author":"Ehsani","year":"2025","journal-title":"Arch Dermatol Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12865-022-00486-4","article-title":"CD4, CD8 and natural killer cells are depressed in patients with alopecia areata: their association with disease activity.","volume":"23","author":"Younes","year":"2022","journal-title":"BMC Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.0022-202X.2005.23692.x","article-title":"Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)\/CD25(-) cells promote systemic alopecia areata and CD4(+)\/CD25(+) cells blockade disease onset in the C3H\/HeJ mouse model.","volume":"124","author":"McElwee","year":"2005","journal-title":"J Invest Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.3390\/ijerph15122882","article-title":"Epigallocatechin-3 gallate inhibits STAT-1\/JAK2\/IRF-1\/HLA-DR\/HLA-B and reduces CD8 MKG2D lymphocytes of alopecia areata patients.","volume":"15","author":"Hamed","year":"2018","journal-title":"Int J Environ Res Public Health."},{"key":"B53","doi-asserted-by":"publisher","first-page":"33432","DOI":"10.18632\/oncotarget.16504","article-title":"SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction.","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e121949","DOI":"10.1172\/jci.insight.121949","article-title":"High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.","volume":"3","author":"de Jong","year":"2018","journal-title":"JCI Insight."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cup.12805","article-title":"CD8+ mycosis fungoides clinically masquerading as alopecia areata.","volume":"43","author":"Amin","year":"2016","journal-title":"J Cutan Pathol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4049\/jimmunol.1100657","article-title":"A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis.","volume":"188","author":"Alli","year":"2012","journal-title":"J Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e94260","DOI":"10.1371\/journal.pone.0094260","article-title":"Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.","volume":"9","author":"Bertolini","year":"2014","journal-title":"PLoS One."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1695618\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:18Z","timestamp":1763097018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1695618\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":57,"alternative-id":["10.3389\/fmed.2025.1695618"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1695618","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1695618"}}